ACTU (Actuate Therapeutics) Moat Score: 2/10 (As of Jun. 27, 2026)


ACTU Actuate Therapeutics Inc ACTU
14 GF Score
Price $1.82
View Full Analysis

What is Actuate Therapeutics Moat Score?

Actuate Therapeutics ACTU -14.29% 14 Moat Score is 2 as of Jun. 27, 2026. GuruFocus rates ACTU with a GF Score™ of 14/100. Among 1,404 Biotechnology companies, Actuate Therapeutics ranks better than 58.12% on this metric.

Actuate Therapeutics has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

Actuate Therapeutics has No Moat: Actuate is an early-stage biotech company with limited market presence and no proven intellectual property advantages. It faces significant competition and lacks durable competitive advantages.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Actuate Therapeutics might have No Moat - Very weak/transient advantages.

Actuate Therapeutics  (NAS:ACTU) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Actuate Therapeutics Moat Score Related Terms

ACTU vs AURX, ESLA, MGX: Moat Score Comparison

For the Biotechnology subindustry, Actuate Therapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Actuate Therapeutics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actuate Therapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where Actuate Therapeutics's Moat Score falls into.


ACTU
14GF Score
Actuate Therapeutics Inc ACTU
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
Actuate Therapeutics (ACTU) has a Moat Score of 2 as of Jun. 27, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Actuate Therapeutics ranks #588 out of 1404 companies in the Biotechnology industry, placing it in the top 41.9%.
Is Actuate Therapeutics' Moat Score too high?
Actuate Therapeutics' current Moat Score is 2. The Biotechnology industry median Moat Score is 2.00. Actuate Therapeutics' value of 2 is 0% at this industry median. Based on the distribution chart, Actuate Therapeutics ranks #588 out of 1404 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Actuate Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Actuate Therapeutics' Moat Score compare to AURX and ESLA?
According to the Biotechnology industry distribution chart, Actuate Therapeutics ranks #588 out of 1404 companies for Moat Score. This puts Actuate Therapeutics in the upper half of its industry. The industry median Moat Score is 2.00. Actuate Therapeutics' value of 2 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,404 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Actuate Therapeutics's current Moat Score of 2 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Actuate Therapeutics's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Actuate Therapeutics stock overvalued right now?
Actuate Therapeutics (ACTU) has a current Moat Score of 2. The current Moat Score is 2 and 0% at the Biotechnology industry median of 2.00. Actuate Therapeutics' overall GF Score™ is 14/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Actuate Therapeutics (ACTU), the current Moat Score is 2 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Actuate Therapeutics Business Description

Address 1751 River Run, Suite 400, Fort Worth, TX, USA, 76107
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
14GF Score

Get the complete analysis for ACTU

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.82
Price